Carolyn Bertozzi and Versant’s new biotech breaks cover with $94M to use protein degraders in ADCs

In the bustling world of antibody-drug conjugates, few biopharmas have revealed ambitions for combining antibodies with protein degraders, rather than chemo or other cytotoxic drugs.

Firefly Bio was unveiled Thursday with a $94 million Series A from Versant Ventures’ discovery unit in Basel, Switzerland, as well as…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks